About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Bavarian Nordic gets European monkeypox approval for smallpox vaccine

NEOsphere Biotechnologies closes financing round

Macao university research finds mRNA vaccine booster offers more protection against Omicron variants

Replay launches with $55M to reprogram biology by writing and delivering big DNA

Australia looks to biotech alliance

Astellas to create new biotech campus in South San Francisco

ADVERTISEMENT

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

Poolbeg Pharma gets approval for severe influenza drug trial

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

Eiger receives European approval for progeria treatment

Vicebio exits stealth to work on next generation RSV vaccine

IVI and Moderna sign MOU for vaccine R&D

ADVERTISEMENT